CO6270265A2 - Polipeptido ace2 recombinante, el cual esta presente como un dimero - Google Patents

Polipeptido ace2 recombinante, el cual esta presente como un dimero

Info

Publication number
CO6270265A2
CO6270265A2 CO10001879A CO10001879A CO6270265A2 CO 6270265 A2 CO6270265 A2 CO 6270265A2 CO 10001879 A CO10001879 A CO 10001879A CO 10001879 A CO10001879 A CO 10001879A CO 6270265 A2 CO6270265 A2 CO 6270265A2
Authority
CO
Colombia
Prior art keywords
present
ace2 polypeptide
recombinant ace2
dimero
recombinant
Prior art date
Application number
CO10001879A
Other languages
English (en)
Inventor
Manfred Schuster
Hans Loibner
Evelyne Janzek-Hawlat
Bernhard Peball
Stefan Stranner
Bettina Wagner
Robert Weik
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/de
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of CO6270265A2 publication Critical patent/CO6270265A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se relacione al polipéptido ACE2 recombinante, donde el polipéptido ACE2 esta presente como un dimero. El dimero se forma especificamente de monomeros glicosilados y se usa para producir productos farmacéuticos con una vida media prolongada. 1.- Un polipéptido ACE2 recombinante, caracterizado porque esta presente como un dimero. 2.- Un polipéptido ACE2 recombinante de conformidad con la reivindicacion 1, caracterizado porque esta presente como un homodimero. 3.- El polipéptido ACE2 recombinante de conformidad con las reivindicaciones 1 o 2, caracterizado porque por lo menos 70% de los sitios de N-glicosilacion glicosilados tienen una estructura, independientemente entre si, seleccionada de las formulas 1 a 8:4.- El polipéptido ACE2 recombinante de conformidad con una de las reivindicaciones 1 a 3, caracterizado porque todos los sitios de N-glicosilacion posibles son glicosilados.
CO10001879A 2007-06-12 2010-01-08 Polipeptido ace2 recombinante, el cual esta presente como un dimero CO6270265A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (de) 2008-04-08 2008-04-08 Ace2 Polypeptid

Publications (1)

Publication Number Publication Date
CO6270265A2 true CO6270265A2 (es) 2011-04-20

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10001879A CO6270265A2 (es) 2007-06-12 2010-01-08 Polipeptido ace2 recombinante, el cual esta presente como un dimero

Country Status (35)

Country Link
US (3) US8586319B2 (es)
EP (3) EP3375872A1 (es)
JP (1) JP5731193B2 (es)
KR (2) KR20160054045A (es)
CN (2) CN101796183A (es)
AT (1) AT505262A1 (es)
AU (1) AU2008261591B2 (es)
BR (1) BRPI0813942B8 (es)
CA (1) CA2692854C (es)
CO (1) CO6270265A2 (es)
CR (1) CR11213A (es)
CY (2) CY1116873T1 (es)
DK (2) DK2543724T3 (es)
DO (1) DOP2009000282A (es)
EA (1) EA027399B1 (es)
EG (1) EG27095A (es)
ES (2) ES2670938T3 (es)
HK (2) HK1255493A1 (es)
HR (2) HRP20151120T1 (es)
HU (2) HUE037877T2 (es)
IL (1) IL202653B (es)
LT (1) LT2543724T (es)
MA (1) MA31472B1 (es)
MX (1) MX2009013472A (es)
MY (1) MY180672A (es)
NO (1) NO2543724T3 (es)
NZ (1) NZ581704A (es)
PL (2) PL2155871T3 (es)
PT (2) PT2543724T (es)
RS (2) RS54340B1 (es)
SI (2) SI2543724T1 (es)
TR (1) TR201808117T4 (es)
UA (1) UA106869C2 (es)
WO (1) WO2008151347A1 (es)
ZA (1) ZA200908751B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
CA2876099A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
ES2732282T3 (es) * 2013-01-14 2019-11-21 Apeiron Biologics Ag Polipéptidos de ECA2 modificados
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
AU2017296352A1 (en) 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
WO2021217120A2 (en) * 2020-04-24 2021-10-28 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
EP4171603A1 (en) * 2020-06-25 2023-05-03 Gliknik Inc. Ace2-fc fusion proteins and methods of use
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
US20220025071A1 (en) * 2020-07-10 2022-01-27 Biomolecular Holdings Llc Tetrahedral antibodies
CN116710560A (zh) * 2020-08-21 2023-09-05 西湖大学 工程化ace2寡聚物及其用途
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022159433A1 (en) 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
WO2023023424A1 (en) * 2021-08-19 2023-02-23 Phenom Pharmaceuticals, Inc. Compositions and methods for treatment of sars cov-2
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
PT2332582E (pt) * 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
WO2004023270A2 (en) 2002-09-09 2004-03-18 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (de) * 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2108695A1 (de) * 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 Polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
IL202653B (en) 2018-01-31
AT505262A1 (de) 2008-12-15
US20100310546A1 (en) 2010-12-09
HK1136602A1 (en) 2010-07-02
EP2543724A3 (de) 2013-02-20
NZ581704A (en) 2012-05-25
RS57292B1 (sr) 2018-08-31
NO2543724T3 (es) 2018-08-18
HK1255493A1 (zh) 2019-08-16
MX2009013472A (es) 2010-06-25
DOP2009000282A (es) 2010-03-31
CN104450654A (zh) 2015-03-25
CA2692854A1 (en) 2008-12-18
DK2155871T3 (en) 2015-11-09
MA31472B1 (fr) 2010-06-01
KR20160054045A (ko) 2016-05-13
MY180672A (en) 2020-12-05
KR20100040809A (ko) 2010-04-21
HUE037877T2 (hu) 2018-09-28
EA201000002A1 (ru) 2010-08-30
ES2550390T3 (es) 2015-11-06
EP3375872A1 (de) 2018-09-19
SI2155871T1 (sl) 2015-11-30
AU2008261591B2 (en) 2014-08-07
CY1120426T1 (el) 2019-07-10
CA2692854C (en) 2017-07-04
EG27095A (en) 2015-05-28
HRP20180856T1 (hr) 2018-08-24
PL2155871T3 (pl) 2015-12-31
US10716833B2 (en) 2020-07-21
ZA200908751B (en) 2010-07-28
JP5731193B2 (ja) 2015-06-10
HRP20151120T1 (en) 2015-11-20
EA027399B1 (ru) 2017-07-31
BRPI0813942B8 (pt) 2021-05-25
BRPI0813942B1 (pt) 2019-08-20
BRPI0813942A2 (pt) 2014-12-30
JP2011519264A (ja) 2011-07-07
EP2155871B1 (de) 2015-08-12
RS54340B1 (en) 2016-02-29
IL202653A0 (en) 2011-08-01
US20180289779A1 (en) 2018-10-11
WO2008151347A1 (de) 2008-12-18
HUE028012T2 (en) 2016-11-28
US8586319B2 (en) 2013-11-19
CY1116873T1 (el) 2017-04-05
CR11213A (es) 2010-04-20
EP2543724B1 (de) 2018-03-21
PL2543724T3 (pl) 2018-08-31
KR101682240B1 (ko) 2016-12-06
DK2543724T3 (en) 2018-05-28
LT2543724T (lt) 2018-06-25
EP2155871A1 (de) 2010-02-24
US20140099297A1 (en) 2014-04-10
PT2543724T (pt) 2018-06-11
PT2155871E (pt) 2015-10-26
EP2543724A2 (de) 2013-01-09
SI2543724T1 (en) 2018-07-31
TR201808117T4 (tr) 2018-07-23
CN101796183A (zh) 2010-08-04
ES2670938T3 (es) 2018-06-04
AU2008261591A1 (en) 2008-12-18
UA106869C2 (uk) 2014-10-27

Similar Documents

Publication Publication Date Title
CO6270265A2 (es) Polipeptido ace2 recombinante, el cual esta presente como un dimero
CR10889A (es) Antagonistas de activina-actrii y sus usos para incrementar los niveles de globulos rojos en la sangre
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
CR7765A (es) Queso crema bajo en proteina
GT200600042A (es) Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
NI200700259A (es) Métodos para el tratamiento y prevención de fibrosis
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
GT200300097A (es) Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
EA201000497A1 (ru) Противомалярийная фармацевтическая композиция
GT200900282A (es) [4(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo sales de sulfonilurea, y las formas y métodos relacionados con el mismo.
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo
GT200400188A (es) 5-arilpirimidinas como agentes anticancerigenos
DOP2010000098A (es) Nuevas composiciones a base de taxoides
SE0602649L (sv) Sugrör
GT200600325A (es) Procedimiento para la preparacion de haluros de sulfonilo y sulfonamidas
GT200400232A (es) Metodos y composiciones para la inhibicion de selectina
UY30368A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
BR102016009098A2 (pt) ?montagem produtora de luz para um veículo?
ECSP088897A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización
AR113549A1 (es) Plataforma de pesaje
BRPI0400985A (pt) Mandìbula para britadores

Legal Events

Date Code Title Description
FC Application refused